Pricing Log in Create free account

CytomX Therapeutics, Inc. (CTMX) vs Valneva SE Sponsored ADR (VALN)

CytomX Therapeutics, Inc. and Valneva SE Sponsored ADR are both Biotechnology companies. CytomX Therapeutics, Inc. and Valneva SE Sponsored ADR are of similar size ($560.4M and $525.1M). CytomX Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Valneva SE Sponsored ADR trades at 59.7×. Valneva SE Sponsored ADR grew revenue faster over the last twelve months: −53.2% against −87.0%. Valneva SE Sponsored ADR has the higher net margin (−12.0% vs −451.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Valneva SE Sponsored ADR leads on 12 and CytomX Therapeutics, Inc. on 5.

Valuation

Metric CTMX VALN Biotechnology median
P/E n/m 59.68 8.50
P/S 27.16 3.05 9.71
P/B 1.65 5.30 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 42.91 0.64
EV/Sales 9.28 3.49 9.21
Earnings yield (22.03%) 1.68% (33.15%)
Free cash flow yield (16.63%) (11.78%) (25.50%)

Profitability

Metric CTMX VALN Biotechnology median
Gross margin 100.00% 38.28% 65.16%
Operating margin (476.19%) 13.56% 0.00%
Net margin (451.62%) (12.01%) 0.00%
Free cash flow margin (450.27%) 0.00% 0.00%
Return on equity (39.18%) 0.00% (56.36%)
Return on assets (29.72%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CTMX VALN Biotechnology median
Revenue growth (TTM) (87.03%) (53.16%) 6.02%
EPS growth (last fiscal year) (139.47%) (805.88%) 30.26%
Revenue growth, 5-year CAGR (5.36%) 9.41% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CTMX VALN Biotechnology median
Debt to equity 0.00 2.27 0.00
Current ratio 9.36 2.16 4.72
Net debt to EBITDA 5.91 (1.15) 0.96

Dividend

Metric CTMX VALN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CTMX VALN Biotechnology median
Market cap 525.14m 560.39m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack